BeiGene, Ltd. (BGNE)
After hours:
| Previous close | 235.43 |
| Open | 241.10 |
| Bid | 239.99 x 100 |
| Ask | 240.66 x 100 |
| Day's range | 234.86 - 246.55 |
| 52-week range | 126.97 - 248.16 |
| Volume | |
| Avg. volume | 303,607 |
| Market cap | 26.387B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.94 |
| Earnings date | 13 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 274.60 |
ZacksBeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?
BeiGene (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Simply Wall St.3 Stocks That May Be Trading Below Intrinsic Value By Up To 48.2%
With global markets reaching new highs following the Federal Reserve's recent rate cut, investors are eagerly seeking opportunities that may be trading below their intrinsic value. In this favorable market environment, identifying undervalued stocks can be particularly rewarding, as these investments have the potential to offer significant upside when their true worth is recognized.
Business WireBeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
SAN MATEO, Calif., September 26, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recognizes the favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for the first-line treatment of patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1 (>1%) and gastric/gastroes
